Michael McElhaugh
Chief Executive Officer presso ARBUTUS BIOPHARMA CORPORATION
Patrimonio netto: 3 M $ in data 31/03/2024
Posizioni attive di Michael McElhaugh
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 01/01/2024 | - |
| Chief Executive Officer | 01/01/2024 | - | |
| Chief Operating Officer | 01/11/2022 | - | |
| President | 01/01/2024 | - | |
| Corporate Officer/Principal | 01/12/2018 | 01/11/2022 | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Executive Officer | 01/01/2024 | - |
| President | 01/01/2024 | - |
Storia della carriera di Michael McElhaugh
Precedenti posizioni note di Michael McElhaugh
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/09/2008 | 01/03/2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Operating Officer | 01/05/2012 | - |
| Founder | 01/05/2012 | - |
Formazione di Michael McElhaugh
| Thomas Jefferson University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
Posizioni
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 2 |
| Chief Executive Officer | 2 |
Settori
| Health Technology | 5 |
| Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
- Borsa valori
- Insiders
- Michael McElhaugh
- Esperienza
